7
|
Ottesen AH, Carlson CR, Eken OS, Sadredini M, Myhre PL, Shen X, Dalhus B, Laver DR, Lunde PK, Kurola J, Lunde M, Hoff JE, Godang K, Sjaastad I, Pettilä V, Stridsberg M, Lehnart SE, Edwards AG, Lunde IG, Omland T, Stokke MK, Christensen G, Røsjø H, Louch WE. Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca 2+-Dependent Arrhythmia. Circ Arrhythm Electrophysiol 2020; 12:e007045. [PMID: 30943765 DOI: 10.1161/circep.118.007045] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Circulating SN (secretoneurin) concentrations are increased in patients with myocardial dysfunction and predict poor outcome. Because SN inhibits CaMKIIδ (Ca2+/calmodulin-dependent protein kinase IIδ) activity, we hypothesized that upregulation of SN in patients protects against cardiomyocyte mechanisms of arrhythmia. METHODS Circulating levels of SN and other biomarkers were assessed in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT; n=8) and in resuscitated patients after ventricular arrhythmia-induced cardiac arrest (n=155). In vivo effects of SN were investigated in CPVT mice (RyR2 [ryanodine receptor 2]-R2474S) using adeno-associated virus-9-induced overexpression. Interactions between SN and CaMKIIδ were mapped using pull-down experiments, mutagenesis, ELISA, and structural homology modeling. Ex vivo actions were tested in Langendorff hearts and effects on Ca2+ homeostasis examined by fluorescence (fluo-4) and patch-clamp recordings in isolated cardiomyocytes. RESULTS SN levels were elevated in patients with CPVT and following ventricular arrhythmia-induced cardiac arrest. In contrast to NT-proBNP (N-terminal pro-B-type natriuretic peptide) and hs-TnT (high-sensitivity troponin T), circulating SN levels declined after resuscitation, as the risk of a new arrhythmia waned. Myocardial pro-SN expression was also increased in CPVT mice, and further adeno-associated virus-9-induced overexpression of SN attenuated arrhythmic induction during stress testing with isoproterenol. Mechanistic studies mapped SN binding to the substrate binding site in the catalytic region of CaMKIIδ. Accordingly, SN attenuated isoproterenol induced autophosphorylation of Thr287-CaMKIIδ in Langendorff hearts and inhibited CaMKIIδ-dependent RyR phosphorylation. In line with CaMKIIδ and RyR inhibition, SN treatment decreased Ca2+ spark frequency and dimensions in cardiomyocytes during isoproterenol challenge, and reduced the incidence of Ca2+ waves, delayed afterdepolarizations, and spontaneous action potentials. SN treatment also lowered the incidence of early afterdepolarizations during isoproterenol; an effect paralleled by reduced magnitude of L-type Ca2+ current. CONCLUSIONS SN production is upregulated in conditions with cardiomyocyte Ca2+ dysregulation and offers compensatory protection against cardiomyocyte mechanisms of arrhythmia, which may underlie its putative use as a biomarker in at-risk patients.
Collapse
Affiliation(s)
- Anett H Ottesen
- Division of Medicine, Akershus University Hospital, Lørenskog, Norway (A.H.O., P.L.M., J.E.H., T.O., H.R.).,Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - Cathrine R Carlson
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - Olav Søvik Eken
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - Mani Sadredini
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - Peder L Myhre
- Division of Medicine, Akershus University Hospital, Lørenskog, Norway (A.H.O., P.L.M., J.E.H., T.O., H.R.).,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - Xin Shen
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - Bjørn Dalhus
- Department for Microbiology, Clinic for Laboratory Medicine (B.D.), Oslo University Hospital, Norway.,Department for Medical Biochemistry, Institute for Clinical Medicine (B.D.), University of Oslo, Norway
| | - Derek R Laver
- School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, New South Wales, Australia (D.R.L.)
| | - Per Kristian Lunde
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - Jouni Kurola
- Division of Intensive Care Medicine, Kuopio University Hospital, Finland (J.K.)
| | - Marianne Lunde
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - Jon Erik Hoff
- Division of Medicine, Akershus University Hospital, Lørenskog, Norway (A.H.O., P.L.M., J.E.H., T.O., H.R.)
| | - Kristin Godang
- Section of Specialized Endocrinology, Department of Endocrinology (K.G.), Oslo University Hospital, Norway
| | - Ivar Sjaastad
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway.,K.G. Jebsen Center for Cardiac Research (I.S., G.C., W.E.L.), University of Oslo, Norway
| | - Ville Pettilä
- Division of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki & Helsinki University Hospital, Finland (V.P.)
| | - Mats Stridsberg
- Department of Medical Sciences, Uppsala University, Sweden (M. Stridsberg)
| | - Stephan E Lehnart
- Heart Research Center Goettingen, University Medicine Center Goettingen, Germany (S.E.L.)
| | - Andrew G Edwards
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway.,Simula Research Laboratory, Fornebu, Norway (A.G.E)
| | - Ida G Lunde
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - Torbjørn Omland
- Division of Medicine, Akershus University Hospital, Lørenskog, Norway (A.H.O., P.L.M., J.E.H., T.O., H.R.).,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - Mathis K Stokke
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - Geir Christensen
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway.,K.G. Jebsen Center for Cardiac Research (I.S., G.C., W.E.L.), University of Oslo, Norway
| | - Helge Røsjø
- Division of Medicine, Akershus University Hospital, Lørenskog, Norway (A.H.O., P.L.M., J.E.H., T.O., H.R.).,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway
| | - William E Louch
- Institute for Experimental Medical Research (A.H.O., C.R.C., O.S.E., M. Sadredini, X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., M.K.S., G.C., W.E.L.), Oslo University Hospital, Norway.,Center for Heart Failure Research (A.H.O., C.R.C., O.S.E., M. Sadredini, P.L.M., X.S., P.K.L., M.L., I.S., A.G.E., I.G.L., T.O., M.K.S., G.C., H.R., W.E.L.), University of Oslo, Norway.,K.G. Jebsen Center for Cardiac Research (I.S., G.C., W.E.L.), University of Oslo, Norway
| |
Collapse
|
8
|
Wei WL, Hou JJ, Wang X, Yu Y, Li HJ, Li ZW, Feng ZJ, Qu H, Wu WY, Guo DA. Venenum bufonis: An overview of its traditional use, natural product chemistry, pharmacology, pharmacokinetics and toxicology. JOURNAL OF ETHNOPHARMACOLOGY 2019; 237:215-235. [PMID: 30905791 DOI: 10.1016/j.jep.2019.03.042] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/20/2018] [Revised: 03/16/2019] [Accepted: 03/16/2019] [Indexed: 06/09/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE The animal medicine of Venenum Bufonis (VB), a product of the secretions of Bufo gargarizans Cantor or B. melanostictus Schneider, has long been used as a traditional Chinese medicine (TCM) for the treatment of sunstroke and faint, acute filthy disease - abdominal pain or vomiting and diarrhea, etc. AIM OF THE REVIEW: This review is aimed at providing the comprehensive and up-to-date information of VB as regards its ethnopharmacological uses, constituents and their metabolism, pharmacokinetics, pharmacology and toxicology, all of which could be used as fundamental data for future research as well as development of new drugs. MATERIALS AND METHODS The information and data about the studies of VB were collected from scientific journals, material medica, historical documents, library, and electronic databases (PubMed, Google Scholar, Science Direct, Researchgate, Web of Science and CNKI). RESULTS To date, about 142 bufadienolides and 16 indole alkaloids have been isolated from VB in total. The extract and isolated compounds showed a wide range of in vitro and in vivo pharmacologic effects, such as cardiotonic, anti-tumor, antinociceptive, anti-inflammatory, anesthetic and antimicrobial activities. Especially, bufadienolides have been extensively studied due to its powerful anti-tumor activities against various cancer cells. Furthermore, their metabolites and metabolic pathways were concluded in detail, and the main metabolic pathways of bufadienolides were hydroxylation, 3-isomerization, 3-keto, 16-hydrolyzation, 3-O-sulfate and 3-O-glucuronide. CONCLUSIONS Although VB possesses significant anti-tumor effect against various cancer cell lines, the development of new drugs still remains to be a challenge due to its pharmacodynamic effects in vivo, druggability and toxicology. The main problem lies in its side effects in vivo, poor bioavailability, fast metabolism, cardiotoxicity and neurovirulence. Besides, studies on its metabolism and toxicology in vitro and in vivo, as well as clinical trials should be further conducted for the new drug development and the establishment of optimal dosage of consumption of its administration.
Collapse
Affiliation(s)
- Wen-Long Wei
- Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China
| | - Jin-Jun Hou
- Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China
| | - Xia Wang
- Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China
| | - Yang Yu
- Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China
| | - Hao-Jv Li
- Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China
| | - Zhen-Wei Li
- Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China
| | - Zi-Jin Feng
- Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China
| | - Hua Qu
- Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China
| | - Wan-Ying Wu
- Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China.
| | - De-An Guo
- Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China.
| |
Collapse
|